Under conditions of persistent antigen exposure, BCMA-targeted CAR-T cells engineered with an OX40 co-stimulatory domain demonstrate superior proliferative capacity and more sustained anti-tumor activity compared to those incorporating a 4-1BB domain [86]. Here, TNFRSF17 is linked to neoplasm.